MedTrace Logo

When to Apply to Which Patient in MSC?

NCT05240430 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2022-02-15

No results posted yet for this study

Summary

Mesenchymal stem cell (MSC) therapy is among the promising treatments for acute respiratory distress syndrome (ARDS). Our study aimed to investigate the clinical efficacy of MSC treatment in COVID-19 patients, to determine when this treatment can be applied to which patient, and to evaluate its contribution to prognosis.

Conditions

  • COVID-19 Acute Respiratory Distress Syndrome

Interventions

DRUG

Mesenchymal Stem Cell Antigen-1, Human

Human umbilical cord-derived MSCs were used in the study. MSCs were prepared/obtained/produced/provided by Atigen-Cell Technology Center, Trabzon, Turkey. MSC for patients was calculated as a single dose, 1x106 cells per kilogram. MSC was infused in 100 ml of normal saline at 2 ml/min over 40 min, as described in previous studies

Sponsors & Collaborators

  • Trabzon Kanuni Education and Research Hospital

    lead OTHER

Principal Investigators

  • Ahmet AKYOL, MD · Trabzon Kanuni Training and Research Hospital, University of Healthy Sciences, Trabzon, Turkey

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2022-02-28
Completion
2022-03-31
FDA Drug
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05240430 on ClinicalTrials.gov